Evidence map›Paper›PMID 41112957›Full record

ArticleJournal of scleroderma and related disorders2025

Incidence and prevalence of juvenile SSc in the United States: An analysis by age group.

John Mattson, Haikun Bao, Mary Flack, Karen Coeytaux

Abstract read
In one paragraph

Article in Journal of scleroderma and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

John MattsonBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.ORCID https://orcid.org/0009-0008-1281-5780
Haikun BaoBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
Mary FlackBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
Karen CoeytauxBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.ORCID https://orcid.org/0000-0002-1325-8807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Systemic sclerosis is a rare autoimmune connective tissue disease characterized by progressive skin and organ fibrosis, and diffuse fibro-proliferative vascular modifications. Roughly 2%-10% of systemic sclerosis cases develop during juvenile years (under 18 years of age); however, there are limited data on the incidence and prevalence of juvenile systemic sclerosis. This analysis assessed the incidence and prevalence of juvenile systemic sclerosis in the United States, overall and by age group. Methods: Juvenile systemic sclerosis patients with ⩾2 medical diagnostic claims for systemic sclerosis within a 1-year period were identified from the Optum de-identified Clinformatics Results: Forty-eight incident and 103 prevalent cases were identified. Overall, the age- and sex-adjusted incidence and prevalence of juvenile systemic sclerosis were 2.4 per million person-years and 12.0 per million, respectively. When stratified by age group, incidence and prevalence rates increased with age in the overall and subgroup analyses. Conclusion: In this analysis, incidence and prevalence rates of juvenile systemic sclerosis increased with age. Increasing incidence and prevalence were observed from 10 years old and from 6 years old, respectively. While the overall data are broadly consistent with previous reports, these data provide new information on the estimated incidence and prevalence of juvenile systemic sclerosis by age group.

Indexed as

claimsdatabaseincidencejSScjuvenile systemic sclerosisOptumprevalenceUnited States

Identifiers

PMID41112957
PMCPMC12531193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.